Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor expression-enhancing protein 6 (REEP6) is a member of the REEP family of endoplasmic reticulum (ER)-resident accessory proteins that shape the membrane architecture of the ER and facilitate the trafficking and localization of specific membrane proteins, including guanylate cyclases essential for retinal phototransduction. REEP6 is localized to the inner segment and outer plexiform layer of rod photoreceptors in the retina. Loss of REEP6 function—via rare recessive mutations—leads to severe retinal degeneration (retinitis pigmentosa) in humans and mice, primarily through disruption of cGMP homeostasis and induction of ER stress, followed by photoreceptor cell death. REEP6 is not itself a classic receptor or enzyme but is essential for the stability, sorting, and homeostasis of other key photoreceptor proteins and organelles. There are no known direct drug interactions, and it is not presently considered a therapeutic target, but its genetic status serves as a biomarker for inherited retinal dystrophy[1][2][3].
Null. No drugs reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor expression-enhancing protein 6 (REEP6).